23andMe Target of Unusually High Options Trading (NASDAQ:ME)

23andMe Holding Co. (NASDAQ:ME) was the recipient of unusually large options trading on Wednesday. Stock traders bought 7,134 call options on the stock. This is an increase of 812% compared to the average daily volume of 782 call options.

Institutional Investors Weigh In On 23andMe

A number of institutional investors and hedge funds have recently bought and sold shares of ME. FNY Investment Advisers LLC acquired a new position in 23andMe in the fourth quarter valued at $26,000. Leavell Investment Management Inc. acquired a new position in 23andMe in the 4th quarter valued at about $32,000. MassMutual Private Wealth & Trust FSB purchased a new stake in 23andMe during the 4th quarter valued at approximately $40,000. Virtu Financial LLC purchased a new stake in 23andMe during the 4th quarter valued at approximately $49,000. Finally, Geode Capital Management LLC lifted its position in 23andMe by 0.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,246,093 shares of the company’s stock worth $1,476,000 after acquiring an additional 28,252 shares during the period. 36.10% of the stock is owned by hedge funds and other institutional investors.

23andMe Stock Down 2.1 %

23andMe stock traded down $0.04 during midday trading on Wednesday, reaching $1.87. The company’s stock had a trading volume of 40,489 shares, compared to its average volume of 265,631. The business has a 50-day simple moving average of $2.68 and a 200-day simple moving average of $4.02. The company has a market cap of $50.17 million, a P/E ratio of -0.12 and a beta of 1.19. 23andMe has a fifty-two week low of $1.34 and a fifty-two week high of $12.76.

23andMe (NASDAQ:ME) last announced its quarterly earnings results on Tuesday, January 28th. The company reported ($1.02) earnings per share (EPS) for the quarter. 23andMe had a negative net margin of 183.39% and a negative return on equity of 170.07%.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 23andMe in a report on Friday, March 7th.

23andMe Company Profile

23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.